INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin´s lymphoma accounting approximately for 40% cases in adult patients. [1] [2] [3] Despite having similar morphologic appearance, genetic and molecular research gave new insights to this disease. Currently it is known that DLBCL is not a single entity but a heterogeneous group of lymphoid malignancies. The 2008 World Health Organization classification acknowledges several subtypes of DLB-CL according to the heterogeneity of molecular pathogenesis, clinical behavior and prognosis. The broader category is DLBCL not otherwise specified (NOS). 3 It is predictable that in the years to come further entities will be established, as the body of knowledge regarding the tumoral biology grows and several molecular subtypes, with distinct intracellular oncogenic pathways will be recognized. 4, 5 Despite our improved understanding of DLBCL diversity the clinical practice remains remarkably uniform. Regarding prognosis several prognostic models and biomarkers were investigated but lack validation. [6] [7] [8] [9] While one can speculate that improved prognostication will be crucial to allow individualized risk-adapted therapy in the future, at the present time the International Prognostic Index (IPI), based on clinical On the other hand a molecular tailored treatment approach is still far from clinical routine practice, despite several clinical trials are investigating this. [12] [13] [14] [15] Currently, the standard treatment approach is combination chemotherapy and the monoclonal antibody rituximab. [16] [17] [18] [19] [20] [21] The introduction of immunochemotherapy as frontline treatment has significantly increased complete remission rate and survival. Depending on age at diagnosis and other prognostic factors, up to 70% patients can achieve a complete remission (CR).
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Despite the high CR rate, the outcome of patients with intermediate or high IPI is still dismal. For these patients the better treatment strategy is uncertain and there is a need for randomized prospective clinical trials in the rituximab era. 21 Several different approaches deviating from standard R-CHOP were proposed in the literature: shorten the interval of administration of chemotherapy drugs (R-CHOP 14) or protocols based on higher dose-intensity (R-ACVBP, R-CHOEP). Also, in the view of the established benefit of autologous stem cell transplant (Auto-SCT) in salvage setting, this strategy has been explored as upfront therapy in poor-risk patients. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Based on this studies our department offered systematically Auto-SCT as first line consolidation treatment in young patients with IPI ≥ 2 during the period considered in this review. All these strategies raise concerns of acute and delayed toxicity. So far, better therapeutic alternatives to R-CHOP, without substantial additional toxicity, have not been found.
In the setting of relapsed or refractory disease, the prognosis is poor. A salvage regimen followed in responsive patients by high dose treatment with stem cell support is recommended with curative intent. 20, [32] [33] [34] [35] [36] The aim of this study was to review twenty years of one single center experience with Auto-SCT in DLBCL. It reflects the clinical routine reality and contributes to a better understanding of the outcome of these patients. Also, the role of Auto-SCT as a frontline therapy remains to be defined and the authors hope to contribute to the body of experience with transplantation in this setting (review of 64 high risk patients transplanted in first CR).
MATERIALS AND METHODS
This study was a retrospective single center analysis including all consecutive Auto-SCT performed in adult patients with DLBCL, between October 1992 and December 2012. Data were collected from the service database and medical records. Statistical analysis was performed with SPSS v21. Event-free and overall survival was analyzed by the log-rank test and the results were expressed as Kaplan-Meier plots. A univariate analysis was performed to assess prognostic factors before Auto-SCT. A multivariate analysis was performed to evaluate the impact of the different prognosis variables.
During the considered period 152 Auto-SCT were performed in various histological subtypes of DLBCL. We included in the statistical analysis 113 patients with DLBCL not otherwise specified and excluded all the histological variants (primary mediastinal large B-cell lymphoma and histological transformation of 'low grade' lymphomas). Considering the IPI at diagnosis in the patients in 1 st complete remission and disease status at transplantation, the patients were divided in four groups: 1) patients in first complete remission after first line chemotherapy and with IPI > 1; 2) patients in first complete remission after two or more lines of chemotherapy; 3) patients in second complete remission; 4) patients not fitting in the other groups.
RESULTS
The median age at the time of Auto-SCT was 49 years (16 -67). The majority of patients were males (n = 68). The majority of patients presented advanced stage (85%) and IPI 2 or 3 (47% and 30% respectively) at diagnosis ( Table  1 ).
The distribution of the patients according to the four groups considered and IPI at diagnosis is shown in Table 2 Rituximab was used in 78 patients before Auto-SCT (66%). The most frequently used first line chemotherapy was R-CHOP (n = 71) and CHOP (n = 28). High dose chemotherapy consisted of standard BEAM regimen (n = 93) or FEAM (n = 20). Hematopoietic stem cells were collected from peripheral blood (PBSC) (n = 100), bone marrow (BM) (n = 2), and PBSC + BM (n = 11). Sixty seven transplants (59%) were performed in the last five years of the period. The median follow up of patients still alive was 34 months (1 -221). The overall survival (OS) at one, three and five years was 84.6% (± 3.4); 75,1%(± 4.4); 73%(± 4.8) respectively. (Fig. 1 ). Significant differences in OS were found among the 4 groups considered (p = 0.001) ( Table 3) .
The OS of the group one was not significantly different from the group two or three; the difference to the group four was significant (p < 0.001); the OS was also significant between group two and four (p = 0.014); this difference was not significant between group two and three (p = 0.4) or group three and four (p = 0.067).
The disease free survival (DFS) at one, three and five years was 84% (± 4); 80% (± 4); 75% (± 5), respectively. Causes of death were: relapse/progression (n = 17); nonrelapsed mortality (n = 8); and secondary neoplasia (n = 1, myelodysplastic syndrome) - Table 3 . In univariate analysis, OS was significantly longer if: early stage at diagnosis, less than two chemotherapy lines before Auto-SCT, disease status before Auto-SCT in CR, first line chemotherapy with RCHOP and use of PBSC. However, when performing multivariate analysis the differences became non-significant.
DISCUSSION
The aim of this study was to review one single center experience with Auto-SCT in DLBCL. Our results clearly demonstrate that the outcome of patients treated with Auto-SCT is dependent on disease status before transplantation, consistent with the published literature. 31 Failure to achieve CR with first line standard immunochemotherapy is considered poor prognostic characteristic. However in our series it did not have a relevant impact in the outcome if the patient achieved CR with second line chemotherapy (Group two). Even though in the univariate analysis we found a better outcome in patients that had received rituximab (p = 0.009), our data does not allow precise measurements specially because the broad temporal span of this series.
While it is well known that patients with IPI ≥ 2 at diagnosis have a worse outcome there is a lack of knowledge regarding the best treatment option in this setting. 8 Auto-SCT as first line consolidation treatment is an option in young patients but the value of upfront Auto-SCT is yet to be determined and remains experimental. [25] [26] [27] [28] [29] [30] [31] Recently SWOG-intergroup 9 704 trial failed to show improved OS, though EFS was seen. 32 Our data shows that this group of patients (Group one) experienced good OS with this treatment strategy. Toxicity is a concern and there is no solid data comparing prospectively upfront Auto-SCT consolidation versus first line treatment with high dose/intensive chemotherapy protocols alternative to standard R-CHOP. In our population non-relapsed mortality was in the expected range, consistent with the published literature. The morbidity and mortality of Auto-SCT must be considered when this treatment is proposed.
At relapse salvage chemotherapy followed by Auto-SCT is the standard second line treatment. This strategy can rescue many patients if the disease remains chemosensitive. 20, [33] [34] [35] [36] In our series, as expected, patients with refractory disease had a dismal prognosis, even with high-dose therapy.
CONCLUSION
In spite of the improved outcome in the rituximab era, many patients with DLBCL still have poor prognosis. Our study shows that Auto-SCT is a good therapy option for high-risk disease, with acceptable non-relapse mortality. About 70% of high risk patients were free of disease after conventional chemotherapy followed by Auto-SCT. While being the standard treatment option in the setting of relapsed disease, much controversy remains about the role of Auto-SCT as an upfront treatment option. Also, since most studies addressing Auto-SCT were performed in the pre-rituximab era, there is a need to redefine the role of this treatment strategy nowadays. There is a need to perform randomized trials to determine if Auto-SCT improves the outcome in high-risk patients treated with rituximab based chemotherapy. On the other hand, further knowledge of additional prognosis factors is necessary. Hopefully the incorporation on clinical practice of novel validated biomarkers and functional imaging techniques such as PET scan will in the future help to further stratify young patients with poor risk classical prognosis factors, contributing to select the ones most prone to benefit with upfront Auto-SCT.
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